Last reviewed · How we verify

NCT05654129: BUCCONAFLD

Porphyromonas Gingivalis and Severity of Fibrosis in Patients With Non-alcoholic Fatty Liver Disease

Status unknown NA Last updated 16 December 2022
What this trial tests

NA trial testing saliva samples in Non-Alcoholic Fatty Liver Disease in 182 participants. Status unknown.

Timeline
5 December 2022
Primary endpoint
5 December 2022
5 December 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment182
Start date5 December 2022
Primary completion5 December 2022
Estimated completion5 December 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many studies suggest that Porphyromonas gingivalis, a virulent periodontopathogenic bacterium, is associated with many systemic diseases such as cardiovascular diseases. In addition, a recent study showed the impact of Porphyromonas gingivalis on Non-Alcoholic Steatosis Liver Disease (NASH). It would be responsible for aggravation of non-alcoholic fatty liver disease (NAFLD) by stimulating inflammation in the damaged liver tissue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of saliva samples

Trials testing the same drug.

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05654129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing